Sucralose Sweetener and Gut Bacteria in People With Crohn's Disease
Tests how sucralose changes gut bacteria in adults with Crohn's disease.
Plain-language title generated from the registry record
Registry title: Non-nutritive Sweeteners in Inflammatory Bowel Disease
Key facts
- Where
- Chagrin Falls, Cleveland, and Westlake, United StatesSee the 3 sites
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 70 years old?
Source: NCT07769437, who can take part
Where in United States
- UH Minoff Health CenterChagrin Falls, United StatesTaking people
- University Hospitals Cleveland Medical Center*Cleveland, United StatesTaking people
- UH Westlake Health CenterWestlake, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- University Hospitals Cleveland Medical Center
- Trial code
- NCT07769437
- Record updated
- 25 September 2026
- Original description
This study will focus on the commonly used non-nutritive sweetener (NNS) sucralose (2 sachets/day resulting in daily dose: sucralose 2.5mg/kg) and its role in changing the gut microbiota in humans with IBD, compared to healthy non-IBD individuals. The investigators will focus on studying IBD patients affected with CD as a proof of principle that could be tested later in other IBD subtype (ulcerative colitis or others specific surgical conditions).Read full original descriptionShow less
The Effect of Non-Nutritive Food Sweeteners in Inflammatory Bowel Disease
This study will focus on the commonly used non-nutritive sweetener (NNS) sucralose (2 sachets/day resulting in daily dose: sucralose 2.5mg/kg) and its role in changing the gut microbiota in humans with IBD, compared to healthy non-IBD individuals. The investigators will focus on studying IBD patients affected with CD as a proof of principle that could be tested later in other IBD subtype (ulcerative colitis or others specific surgical conditions).
Inclusion: Age range from: 18 to 70 years; Male or female; Documented diagnosis of Crohns disease. CD outpatients in remission; Harvey Bradshaw- index in remission (<6 score); Capable of providing consent to participate; Able to complete daily surveys and take oral nutrition; Able to record meal intake; Healthy controls with no diagnosis of IBD or Irritable Bowel Syndrome (IBS).
Exclusion: Known drug abuse; Change in IBD medication within past 4 weeks; Bariatric surgery; Short bowel syndrome; Individuals who lack consent capacity, including the mentally ill, prisoners, cognitively impaired participants, dementia patients; Known parasitic disease of the digestive system; Known active malignancy; History of <1 natural bowel movements per 3 consecutive days; Hospitalized patients; Symptomatic intestinal stricture/narrowing; Presence of an ostomy; Antibiotic use within last 14 days; Well-founded doubt about the patients cooperation; Existing pregnancy or lactation; Unable to access to technology that permits the daily completion of study related activities; Body mass Index <18 kg/m or ≥35 kg/m; Documented C.difficile colitis within four weeks of screening; Phenylketonuria.